Pierluigi Zulli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pierluigi Zulli has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Emiliano Agosteo
Department of Anaesthesia and Intensive Care, San Carlo Clinic, 20037 Paderno Dugnano, Italy
1 shared publication - Enrico Giustiniano
Anesthesia and Intensive Care Department, Humanitas Hospital, Rozzano, 20089 Milan, Italy
1 shared publication - Fulvio Nisi
Department of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
1 shared publication - Massimo Meco
From the Department of Anesthesia and Intensive Care, Clinica San Carlo, Paderno Dugnano, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 156
Beyond Glycemia: Pharmacology-Driven Ketogenesis and Euglycemic DKA with SGLT2 Inhibitors—A Practical Review for Acute Care
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are widely prescribed for type 2 diabetes, heart failure, and chronic kidney disease. A rare but dangerous adverse event is SGLT2i-associated diabetic ketoacidosis, often euglycaemic (euDKA), and therefore easy to miss. This narrative review summarizes mechanisms, triggers (fasting, dehydration, infection, perioperative stress), and ketone-centred pathways for diagnosis, treatment, and prevention in acute-care settings. Management priorities are volume resuscitation, blood β-hydroxybutyrate and acid–base testing, insulin infusion with dextrose to suppress ketogenesis, and electrolyte replacement. Prevention relies on “sick-day” rules, perioperative drug withholding, and a low threshold for ketone testing in any patient with high-anion-gap acidosis, despite normal or mildly elevated glucose.
- 10 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 156
Open AccessBeyond Glycemia: Pharmacology-Driven Ketogenesis and Euglycemic DKA with SGLT2 Inhibitors—A Practical Review for Acute Care
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are widely prescribed for type 2 diabetes, heart failure, and chronic kidney disease. A rare but dangerous adverse event is SGLT2i-associated diabetic ketoacidosis, often euglycaemic (euDKA), and therefore easy to miss. This narrative review summarizes mechanisms, triggers (fasting, dehydration, infection, perioperative stress), and ketone-centred pathways for diagnosis, treatment, and prevention in acute-care settings. Management priorities are volume resuscitation, blood β-hydroxybutyrate and acid–base testing, insulin infusion with dextrose to suppress ketogenesis, and electrolyte replacement. Prevention relies on “sick-day” rules, perioperative drug withholding, and a low threshold for ketone testing in any patient with high-anion-gap acidosis, despite normal or mildly elevated glucose.